GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.
A New Era in Alzheimer's Research: Moving Beyond Amyloid
For decades, the public conversation surrounding Alzheimer’s disease focused almost exclusively on a single culprit: sticky protein deposits in the brain known as amyloid-beta plaques. The dominant theory held that if medicine could simply scrub these plaques away, memory loss and cognitive decline could be halted.
"Lonely Waves" and Genetic Timers: The Latest Alzheimer’s Breakthroughs Decoded
If you opened Google Scholar or picked up the latest issues of Nature Neuroscience or The Lancet Neurology over the past few days, you would spot two huge themes: how our sleep architecture betrays early brain changes, and how combining blood tests with genetics creates an exact clock for when symptoms will start.
The Future of Drug Research Privacy: Navigating Evolving Regulations
Drug research is a critical endeavor that pushes the boundaries of medical science, leading to the development of life-saving treatments and therapies. However, this vital process involves collecting and analyzing sensitive personal data from research participants, raising important ethical and privacy concerns. As technology advances and data collection methods become more sophisticated, the need for robust privacy regulations in drug research is more pressing than ever.
FDA Clears Elecsys pTau217 Blood Test: A Game-Changer for Alzheimer's Diagnosis
The FDA has cleared the Elecsys pTau217 blood test for Alzheimer's. Discover how this single-biomarker assay boosts primary care diagnostic accuracy from 65% to 93%.